Free tool
FAERS Monitor: Xywav
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212690 or its brand name (Xywav, Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate, Sodium Oxybate). Reports on generic versions are filed under their own applications.
Reports
9,150
Serious
7,263
79% of reports
Hospitalization
1,676
Death reported
85
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product administration interrupted1,548
- surgery1,272
- nausea999
- product dose omission issue878
- anxiety699
- intentional dose omission593
- dizziness545
- headache527
- intentional product use issue515
- somnolence492
- vomiting479
- feeling abnormal450
- weight decreased420
- depression416
- fall416
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 6 |
| 2020 | 11 |
| 2021 | 714 |
| 2022 | 1,707 |
| 2023 | 2,062 |
| 2024 | 2,063 |
| 2025 | 1,392 |
| 2026 | 1,190 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,009 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administration interruptedSignal | 1,548 | 564.3 | 535.9 | 698,801 |
| surgerySignal | 1,272 | 51.0 | 48.4 | 61,065 |
| intentional dose omissionSignal | 593 | 48.8 | 45.1 | 27,180 |
| intentional product use issueSignal | 515 | 13.6 | 12.5 | 5,983 |
| product dose omission issueSignal | 878 | 6.9 | 6.5 | 4,456 |
| anxietySignal | 699 | 5.7 | 5.3 | 2,705 |
| somnolenceSignal | 492 | 5.6 | 5.2 | 1,881 |
| feeling abnormalSignal | 450 | 4.3 | 3.9 | 1,157 |
| depressionSignal | 416 | 4.2 | 3.8 | 1,024 |
| weight decreasedSignal | 420 | 3.5 | 3.2 | 742 |
| nauseaSignal | 999 | 2.9 | 2.7 | 1,292 |
| fallSignal | 416 | 2.9 | 2.6 | 515 |
| dizzinessSignal | 545 | 2.5 | 2.3 | 507 |
| vomitingSignal | 479 | 2.3 | 2.1 | 376 |
| headache | 527 | 1.9 | 1.8 | 243 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.